INTERLEUKIN 4 INHIBITS THE PROLIFERATION BUT NOT THE DIFFERENTIATION OF ACTIVATED HUMAN B CELLS IN RESPONSE TO INTERLEUKIN 2

By THIERRY DEFRANCE, BÉATRICE VANBERVLIET, JEAN-PIERRE AUBRY, AND JACQUES BANCHEREAU

From UNICET, Laboratory for Immunological Research, 69572, Dardilly, France

B lymphocytes proliferate and differentiate in response to various lymphokines (1, 2). Progress has been made recently in the understanding of the mechanisms leading to a coordinated immune response due to the availability of some of these lymphokines in recombinant form. IL-2 (3), IFN-γ and α (4–6), TNF-α/β (7, 8), a low molecular weight B cell growth factor (LMW BCGF) (9) and a not yet molecularly defined high molecular weight BCGF (10, 11) have been shown to induce proliferation of activated normal human B cells. IL-2 (12), IL-5 (13), BSF-2/β2-IFN/IL-6 (14–16) have been shown to induce B cell differentiation. It has been recently demonstrated that mouse (17) and human IL-4 (18) have pleiotropic effects. IL-4 induces proliferation of activated B cells (19, 20) and T cells (21, 22) and the expression of the low affinity receptor for IgE (FcεR2/CD23) (23, 24) on resting B cells (25, 26) as well as on certain B cell lines (27). IL-4 was also found to play a central role in the regulation of IgE production in mouse (28) and in human (29), possibly through the release of IgE binding factors (30). IL-4 was also able to induce IgG and IgM production by Staphylococcus aureus strain Cowan-activated B cells (SAC) (31). However, little work has yet dealt with the effect of combinations of lymphokines on the various stages of B cell maturation. We have reported that IFN-γ was enhancing the IL-4-induced proliferation of preactivated B cells, whereas it inhibited the IL-4-induced FcεR2/CD23 expression (20, 25), as well as IgE production (29). IFN-γ was also found to enhance IL-2-mediated B cell differentiation (32, 33). Similarly, partially purified LMW BCGF has been shown to act in concert with IL-4 (20) and IL-2 (34, 35) to promote B cell proliferation.

It was the purpose of this study to investigate the effects of combinations of IL-2 and IL-4 on human B cell proliferation and differentiation. The data indicate that the level of maximal response of preactivated B cells for growth and differentiation is higher with IL-2 than with IL-4 and that IL-4 antagonizes the proliferative effect of IL-2 without altering IL-2-induced differentiation.

Materials and Methods

Factors. Purified IFN-γ (γ4A, 10⁷ U/mg) and purified IL-2 (3 × 10⁶ U/mg) were purchased from Amgen Biologics (Thousands Oaks, CA). 1 U of IL-2 is defined as the amount...
INTERLEUKIN 4 BLOCKS INTERLEUKIN 2 B CELL GROWTH

of IL-2 that induces 50% of maximal [3H]TdR incorporation by IL-2-dependent T cells in culture. The optimal concentration of rIL-2 as determined in the B cell proliferation assay using 1-d preactivated anti-IgM blasts was found to be within the range of 5 to 10 IU/ml. Highly purified rIL-4 (from L 929 cells; 1.2 x 10^7 U/mg) was a kind gift of Dr. Arai (DNAX, Palo Alto, CA) (36). 1 U of IL-4 is defined as the amount of IL-4 required to cause half-maximal stimulation of tritiated thymidine ([3H]TdR) uptake by 5 x 10^5/200 μl T cells, which were preactivated for 3 d with PHA and then extensively washed. Since preliminary experiments had determined that optimal proliferation of anti-IgM blasts was reached with a concentration of purified rIL-4 of 500 U/ml, all preincubation experiments were performed with 500 U/ml of rIL-4. A commercial preparation of a LMW BCGF partially purified from the culture supernatants of PHA-stimulated PBL was obtained from Cellular Products, Inc. (Buffalo, NY) and will be referred to in the text as LMW BCGF.

Mitogens: Insolubilized rabbit anti-human IgM antibody was purchased from Bio-Rad Laboratories (Richmond, CA). Formalinized SAC was purchased as Pansorbin from Calbiochem-Behring Corp. (La Jolla, CA).

Antibodies: The monoclonal and polyclonal antibodies used for phenotyping the B cell preparations were purchased from the following manufacturers: Becton-Dickinson Monoclonal Center (Mountain View, CA): Leu 3 (CD4), Leu 5 b (CD2), Leu 7, Leu 11 (CD16), Leu 12 (CD19), Leu M3 (CD14); Ortho Pharmaceutical Corp. (Raritan, NJ): OKT3 (CD3), OKT4 (CD4), OKT8 (CD8), OKT11 (CD2); Coulter Immunology (Hialeah, FL): B1 (CD20), MO1 (CD11) and MO2 (CD14); Behring AG (Marburg, Federal Republic of Germany): F(ab')2 fragments anti-human Ig coupled to FITC; Grub (Vienna, Austria): FITC-conjugated F(ab')2 fragments of goat anti-mouse Ig used in the indirect immunofluorescence assays. The neutralizing rabbit anti-IL-4 serum was raised in our laboratory and was prepared as follows. Male rabbits were immunized subcutaneously and intramuscularly with 100 μg of *Escherichia coli*-derived rIL-4 in 1 ml CFA (Difco Laboratories, Detroit, MI). The animals were boosted twice with rIL-4. Blood was collected 3 wk after the third immunization and the antiserum was isolated. The Ig fraction was purified on protein A columns (Bio-Rad Laboratories). This antiserum is specific for IL-4: it blocks IL-4-induced IgG/IgM production from SAC blasts (31), IL-4-induced proliferation of T and B cells, and IL-4-induced CD23 expression on the Burkitt lymphoma cell line Jijoye (Chretien, I., A. van Kimmenade, M. K. Pearce, J. Banchereau, J. S. Abrams, submitted for publication). The anti-IL-4 antiserum did not block the biological activities of IL-2 either on T cells (proliferation) or on B cells (proliferation and differentiation). The biological activities of rIL-4 originating from different sources (L929 cells, CHO cells, and *E. coli*) were equally blocked by the anti-IL-4 antiserum. A neutralizing anti-IFN-γ serum raised in the laboratory was used as control.

B Cell Preparations: B cells were isolated from tonsils. Mononuclear cells were separated by standard Ficoll/Hypaque gradient method. B cells were obtained by twice rosetting with aminooethylisothiouronium (AET; Sigma Chemical Co., St. Louis, MO)-treated SRBC. The B cell-enriched populations obtained were typically >95% surface Ig-positive, >95% Bl (CD20) antigen-positive. Less than 1% of the cells expressed the T cell markers CD2, CD3, CD4, and CD8, or the monocyte markers CD11 and CD14. Less than 1% of the cells reacted with the NK cell markers Leu 7 and Leu 11. Purified B cells were then further separated according to size using a discontinuous gradient of Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden) consisting of four solutions (1.075, 1.070, 1.060, and 1.055 g/ml) sequentially layered on top of each other (3 ml of each solution in a 15-ml centrifuge tube, No. 2095; Falcon Labware, Oxnard, CA). 5 x 10^5 purified B cells were laid on top of the gradient and centrifuged for 20 min at 550 g at 20°C. Resting B cells were recovered in the pellet, below the solution of Percoll of the highest density (p > 1.075 g/ml).

Culture Conditions and Assays: Purified B cells were cultured in Iscove's medium enriched with 50 μg/ml human transferrin, 0.5% BSA, 5 μg/ml bovine insulin, oleic, linoleic, and palmitic acids (all from Sigma Chemical Co.), and 2% heat-inactivated FCS (Industrie Biologique Française, Genevilliers, France) as described by Yssel et al. (37) for proliferation assays. For differentiation assays, complete RPMI 1640 medium (Flow Laboratories, Irvine, CA) supplemented with selected heat-inactivated FCS, 2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin (all from Flow Laboratories), 50 μg/ml gentamicin (Laboratoires UNICET, Levallois-Perret, France), and 2% Heps was used.
**Proliferation Assay.** B lymphocytes adjusted at $2 \times 10^6$ cells/ml in enriched Iscove's medium described above were stimulated by insolubilized anti-IgM antibody (10 ug/ml) for 24 h. After activation, B cell blasts were harvested and centrifuged over Ficoll/Hypaque gradient to remove nonviable cells and anti-IgM beads. They were then resuspended at $10^6$ cells/ml in enriched Iscove's medium and dispensed under a volume of 50 µl into wells of microtiter trays. Factors to be tested for their B cell growth-promoting activity were added to reach a final volume of 100 µl. Cells were pulsed with $[^3H]Tdr$ (1 µCi/well, sp act 25 Ci/mmol; CEA, Saclay, France) during the last 16 h of the culture period. $[^3H]Tdr$ uptake was measured by standard liquid scintillation counting techniques after harvesting, using a scintillation counter (LKB Instruments, Bromma, Sweden). The proliferative response of B cell blasts was measured at different intervals from the beginning of culture (from day 2 to day 6). In some experiments, B cell blasts generated after 1 d of preactivation with SAC (0.05%) were also used.

**Cell Cycle Analysis.** The flow cytometric measurement of total DNA content was done using three different techniques: a single staining method with propidium iodide (PI), a single staining method using Hoechst 33 342 as described by Taylor (38), and a double-staining method combining bromodeoxyuridine (BrdUrd), which is incorporated in place of thymidine in DNA during S phase of the cell cycle, and PI, which stains double-stranded DNA. This technique was performed according to Dolbeare et al. (39), with some modifications as described previously (20). DNA histograms, obtained after PI or Hoechst single staining, were analyzed using the mathematical model of Dean and Jett (40). Each DNA histogram was built after acquisition of $2 \times 10^4$ cells.

**Differentiation Assay.** High density tonsillar B cells (p > 1.075 g/ml) at $2 \times 10^6$ cells/ml in complete RPMI 1640 medium (as described above) were stimulated for 2 d with SAC used at a final concentration of 0.05%. To remove nonviable cells and SAC particles, activated B cell blasts were centrifuged (15 min, 550 g) on a gradient consisting of two overlaid solutions of Percoll with densities of 1.077 g/ml and 1.055 g/ml. Viable B cell blasts were recovered at the interface between the two solutions. B cell blasts resuspended in complete RPMI medium were then dispensed (10^5 cells/well) into wells of flat-bottomed microtiter trays (Falcon Labware). Factors to be tested were added in appropriate volumes to reach a final culture volume of 200 µl per well. Each culture point was performed in quadruplicate. Supernatants were harvested 4 d after the onset of the second culture and were kept at ~20°C until Ig levels were determined by ELISA. In some experiments, SAC-activated B cell blasts were further separated into CD25+ (Tac+) and CD25− (Tac−) populations with the FACS after indirect immunofluorescence staining using an anti-CD25 mAb (BI 49.9 mAb; Immunotech, Marseille Luminy, France) and FITC-conjugated F(ab')2 fragments of goat anti-mouse IgG (Grub). The two populations were assayed for proliferation and differentiation using the culture conditions described above.

**Assay of Ig Production.** The cumulative total Ig in the culture was determined by double sandwich ELISA as described by Voller (41). Briefly, microtiter plates (Immunoplates; Nunc, Roskilde, Denmark) were coated with 200 µl of appropriate dilutions of specific anti-IgG, anti-IgM (Behring AG, Marburg, Federal Republic of Germany) or anti-IgA (Biosys, Compiègne, France) in pH 9.6 carbonate buffer overnight at 4°C. After washing, 200-µl serial dilutions of IgG, IgA, and IgM standards (Behring) in PBS Tween 0.05% were added to the respective plates as calibration curves. Dilutions of culture supernatants were added at the same time. After 2 h at room temperature, the plates were washed, and 200 µl of diluted specific alkaline phosphatase-conjugated anti-IgG, anti-IgM (Behring), or anti-IgA (Biosys) was added. After 2 h at room temperature, plates were washed and 200 µl p-nitrophenylphosphate (Sigma Chemical Co.) in diethanolamine buffer was added. Plates were incubated at 37°C, and OD were measured at 405 nm by using an Autoreader (MR 580; Dynatech Laboratories, Inc., Alexandria, VA). OD data were collected and were processed with an Apple IIe computer. Concentrations of Ig in culture supernatants were expressed as nanograms per milliliter.

**Preculture Experiments.** B cell blasts (generated after 24 h of stimulation with insolubilized anti-IgM or SAC) or high density resting B cells were cultured for 24 h at a cell density of $2 \times 10^6$ cells/ml in complete RPMI 1640 medium alone or with rIL-4 (500 U/ml). After preculturing, B cells were centrifuged (15 min, 550 g) on a Percoll solution of 1.053 g/ml.
Viable cells recovered in the pellet were then washed and tested for their capacity to proliferate in response to different factors. When resting B cells were used for preculture experiments, the factors to be tested in the second culture period were used in costimulation with insolubilized anti-IgM antibody (at a final concentration of 10 μg/ml). The proliferative response was routinely measured 3 or 4 d after the onset of the second culture with a $[^3H]$TdR pulse during the last 16 h of culture.

**Results**

*rIL-2-dependent B Cell Proliferation of Preactivated B Cells Is Inhibited by rIL-4.* We have demonstrated earlier that IL-4-induced B cell proliferation was enhanced by semipurified LMW BCGF and IFN-γ (20). Since IL-2 displays B cell growth-promoting activity and has also been demonstrated to act in cooperation with other B cell growth factors (34, 35), we studied the proliferation of activated B cells in response to combinations of rIL-4 and rIL-2. For this purpose, a two-step assay was performed. Highly purified tonsillar B cells were first preactivated for 24 h with insolubilized anti-IgM antibody (10 μg/ml) or SAC, then recultured for an additional period of 3 d with either purified rIL-4, purified rIL-2, or with a combination of both lymphokines. B cell proliferation was monitored by $[^3H]$TdR uptake. As illustrated in Table 1, at optimal concentration of both lymphokines (10 U/ml for rIL-2; 500 U/ml for rIL-4) the levels of $[^3H]$TdR incorporation obtained with rIL-2 were significantly higher than those obtained with rIL-4. Surprisingly, when preactivated B cells were cocultured with rIL-4 and rIL-2, B cell proliferation was lower than that observed with rIL-2 alone and was in most cases comparable to the levels of proliferation obtained with rIL-4 alone (Exps. 1, 2, 4, 5, Table 1). In some experiments (Exps. 3 and 6, Table 1), addition of rIL-4 to rIL-2-stimulated cultures did not reduce the levels of $[^3H]$TdR uptake to these obtained with rIL-4 alone, although the proliferative response to rIL-2 was significantly inhibited. It is also shown (Table 1, Exp. 6) that relatively low amounts of rIL-4 (20 U/ml) can significantly reduce the growth-promoting effect of rIL-2, and that the inhibitory effect of rIL-4 on rIL-2-mediated proliferation is also observed when SAC is used instead of anti-IgM antibody for preactivation of B cells. In some experiments, (one of five, approximately) the proliferation in response to rIL-4 was higher than the proliferation

| Table I |

**rIL-4 Inhibits the rIL-2-mediated Proliferation of Preactivated B Cells**

| rIL-4 Inhibits the rIL-2-mediated Proliferation of Preactivated B Cells |
|--------------------------|
| [H]TdR incorporation     |
| (cpm × 10³ ± SD)         |
| Exp. 1   Exp. 2   Exp. 3   Exp. 4   Exp. 5   Exp. 6 |
| 0        | 0.6 ± 0.2 | 2.8 ± 0.4 | 5.8 ± 0.8 | 5.6 ± 0.2 | 18.2 ± 1.8 | 1.5 ± 0.3 |
| rIL-4    | 11.6 ± 1.0 | 13.2 ± 0.9 | 11.8 ± 0.9 | 12.9 ± 0.4 | 54.7 ± 5.4 | 8.1 ± 0.1 |
| rIL-2    | 31.5 ± 0.8 | 24.5 ± 0.8 | 85.4 ± 4.0 | 28.3 ± 0.6 | 98.1 ± 2.4 | 64.9 ± 1.7 |
| rIL-2 + rIL-4 | 13.8 ± 0.9 | 16.0 ± 0.7 | 43.9 ± 10.0 | 17.9 ± 1.8 | 59.9 ± 3.6 | 32.9 ± 2.5 |

Exps. 1-5 were performed on anti-IgM blasts recovered after 1 d of preactivation. Exp. 6 was performed on SAC blasts recovered after 1 d of preactivation. Each value represents the mean ± SD of triplicate determinations. rIL-2 was used at the final concentration of 10 U/ml. rIL-4 was used at the final concentration of 500 U/ml (Exp. 1-4); 100 U/ml (Exp. 5) and 20 U/ml (Exp. 6).
obtained in response to rIL-2, and the proliferative response to the combination of rIL-2 and rIL-4 was equal to that obtained in response to rIL-4 (not shown here). The cell cycle studies performed using the double-staining BrdUrd/PI, or the single-staining systems (PI or Hoechst 33 342) confirmed the $[^3]$H]TdR uptake data. B cell blasts generated after 2 d of preactivation with SAC were recultured for 3 d with rIL-2 (10 U/ml), rIL-4 (500 U/ml), or rIL-2 + rIL-4. To prevent cycling cells from returning to Go/G1, colcemid (0.1 µg/ml) was added during the last 24 h of the culture. Data displayed in Table II show that rIL-4 significantly reduces the number of cells entering into cycle in response to rIL-2. The inhibition of the rIL-2-mediated B cell proliferation was a function of the concentration of rIL-4 used in the assay (Fig. 1). Kinetics experiments (Fig. 2) demonstrated that the inhibitory effect of rIL-4 was not simply due to a delayed proliferative response to rIL-2, since inhibition could be observed from day 3 up to day 6 after the onset of the culture. When $[^3]$H]TdR uptake was measured at earlier time points (12, 24, and 48 h), it was consistently observed that the peak of $[^3]$H]TdR uptake in response to rIL-2 was not precipitated in the presence of rIL-4 and that rIL-4 could inhibit the growth promoting effect of rIL-2 as early as 24 h after the onset of the culture (data not shown). To rule out the possibility that the antagonizing activity of IL-4 could be mediated via a non-B cell population, phenotypic analysis were performed on SAC blasts that were recultured for 2 additional d with rIL-2 (10 U/ml), rIL-4 (500 U/ml) or rIL-2 plus rIL-4. As illustrated in Fig. 3, immunofluorescence stainings performed with anti-CD2 and anti-CD20 mAbs established that these three cell populations were composed of >95% B cells, whereas T cells remained under detection levels. Taken together these data indicate that IL-4 can at least partially inhibit the proliferative response of activated B cells to IL-2 and suggest that the antagonizing effect of IL-4 is exerted directly on B cells.

**Effect of Preculture with rIL-4 on the Subsequent Proliferative Response of B Cells to rIL-2.** To further explore the inhibitory mechanism of IL-4 on IL-2-induced B cell proliferation, experiments were designed in which B cells were first preincubated with rIL-4 for 24 h before culturing with rIL-2. In the first set of experiments, B cell blasts

| Exp. | rIL-4 | rIL-2 | rIL-4 + rIL-2 |
|------|-------|-------|--------------|
| 1    | 33    | 41    | 35           |
| 2    | 23    | 45    | 24           |
| 3    | 11    | 24    | 13           |
| 4    | 19    | 25    | 19           |

B cells blasts generated after 2 d of preactivation with SAC were further recultured for 3 d with rIL-4 (500 U/ml); rIL-2 (10 U/ml); or rIL-4 + rIL-2. Colcemid (0.1 µg/ml) was added during the last 24 h of the culture to block cells in G2/M. In Exp. 1 and 4, DNA staining was performed using BrdUrd and PI. In Exp. 3, DNA staining was performed with Hoechst 33 342. In Exp. 2, DNA staining was performed with PI.
generated after 24 h of activation with SAC were further incubated for 24 h with or without rIL-4 (500 U/ml) and then recultured for 72 h with rIL-2. The results of these experiments, illustrated in Fig. 4, indicate that pretreatment of SAC-activated B cells with rIL-4 decreases their subsequent proliferation in response to rIL-2. Similarly, B cell blasts preactivated with anti-IgM, which were incubated with rIL-4 for 24 h, displayed a decreased responsiveness to the growth-promoting effect of rIL-2 compared with control blasts incubated with medium (data not shown). In a second set of experiments, high density tonsillar B cells (p > 1.075 g/ml) were precultured with medium alone or with rIL-4 (500 U/ml) for 24 h and then assayed for proliferation in response to rIL-2, rIL-4, or rIL-2 plus rIL-4 in costimulation with insolubilized anti-IgM antibody. The data illustrated in Fig. 5 A show that pretreatment of resting B cells with rIL-4 does not alter their capacity to proliferate subsequently in response to rIL-2 and anti-IgM antibody. Comparable results were obtained when the period of incubation with rIL-4 was prolonged to 48 h (data not shown). The
addition of rIL-4 together with rIL-2 and anti-IgM antibody to rIL-4-pretreated cells during the second culture reduces the rIL-2-mediated proliferation to the level of proliferation induced by rIL-4 itself (Fig. 5 B). This was observed as well for the control samples that had been pretreated with medium during the first culture period.
rIL-4 Does Not Inhibit rIL-2-induced B Cell Differentiation. Since IL-4 can drive activated B cells to differentiate and produce IgG and IgM (31), we next studied whether IL-4 inhibited the IL-2-mediated proliferation of activated B cells by enhancing their differentiation. To test this hypothesis, B cell blasts generated from high density tonsillar B cells after 2 d of activation with SAC were recultured with rIL-4, rIL-2, or the combination of both lymphokines at optimal and suboptimal concentrations. B cell differentiation was monitored by measurement of Ig content (IgG, IgA, and IgM) in the culture supernatants 4 d after the onset of culture. Data illustrated in Table III show that, whatever the concentration of rIL-4 used in combination with rIL-2, no inhibition of rIL-2-mediated IgG production is observed. At optimal con-
### Table III

**rIL-4 Does Not Suppress rIL-2-mediated IgG and IgA Production**

| rIL-4 (U/ml) | IgG $\text{ng/ml} \times 10^{-2}$ | IgA $\text{ng/ml} \times 10^{-2}$ |
|--------------|----------------------------------|----------------------------------|
|              | 0*                               | 0.3                              | 1.25                             | 10                 |
| 0            | 4.6 ± 0.2                        | 17.7 ± 0.3                       | 30.6 ± 4.0                       | 42.0 ± 2.0         |
| 80           | 12.9 ± 0.8                       | 32.3 ± 3.0                       | 40.4 ± 0.5                       | 46.0 ± 2.0         |
| 400          | 17.5 ± 0.6                       | 30.6 ± 2.0                       | 38.9 ± 4.0                       | 35.9 ± 2.0         |
| 2,000        | 21.2 ± 0.9                       | 32.5 ± 2.0                       | 43.7 ± 2.0                       | 46.9 ± 4.0         |

2-d activated SAC blasts were recultured for 4 d with combinations of purified rIL-2 and rIL-4 used at optimal or suboptimal concentrations. Each value represents the mean ± SD of culture quadruplicate. Representative of four experiments.

* rIL-2 (U/ml).
INTERLEUKIN 4 BLOCKS INTERLEUKIN 2 B CELL GROWTH

centration of rIL-2 (10 U/ml), rIL-2-induced IgG production is not affected by rIL-4, whereas at suboptimal concentrations of rIL-2 (0.3 and 1.25 U/ml), the effects of rIL-4 and rIL-2 on IgG production are roughly additive. Similar results were obtained with the production of IgM (data not shown). It is noteworthy that rIL-2-mediated IgA production is not suppressed by rIL-4, which by itself induces only a very weak IgA production. To further explore the apparently contradictory effects of IL-4 on IL-2-mediated proliferation and IL-2-mediated differentiation, B cell blasts recovered after 2 d of preactivation with SAC were sorted according to the expression of CD25. CD25+ and CD25- B cells were then assayed for proliferation and differentiation in response to optimal concentrations of rIL-4, rIL-2, or rIL-2 plus rIL-4. Data illustrated in Table IV demonstrate that the CD25+ population proliferates and differentiates in response to both rIL-2 and rIL-4. In addition, rIL-4 was found to inhibit the proliferation of CD25+ B cells in response to rIL-2 without affecting rIL-2-induced differentiation. The CD25- B cells did not proliferate nor did they differentiate in response to rIL-4, rIL-2, or to the combination of both lymphokines (data not shown). Taken together, these data demonstrate that IL-4 does not inhibit IL-2-mediated B cell proliferation through an enhancement of B cell differentiation.

The Inhibitory Effect of rIL-4 Is Blocked by a Neutralizing Anti-IL-4 Antiserum. To rule out the possibility that the inhibitory effect of rIL-4 could be mediated by contaminants of the rIL-4 preparations, anti-IgM-activated B cells blasts were recultured for 4 d with rIL-2 (10 U/ml), rIL-4 (20 U/ml), rIL-2 plus rIL-4, or rIL-2 plus rIL-4 in the presence of a 1/500 dilution of a neutralizing rabbit polyclonal anti-IL-4 antiserum (Chréti, I., et al., submitted for publication). A neutralizing rabbit anti-IFN-γ antiserum was used as control and added at the same dilution to cultures stimulated with rIL-2 and rIL-4. Additionally, to determine the minimum period of contact required for rIL-4 to develop its inhibitory effect, the anti-IL-4 antiserum was added at different time points during the culture (at the onset of the culture, and 7, 16, 24, or 40 h after the onset of the culture). The results illustrated in Fig. 6 represent the proliferative response of 1-d preactivated anti-IgM blasts stimulated with rIL-2 plus rIL-4 in the presence of the anti-IL-4 antiserum or of the control

Table IV
Effect of the Combined Action of rIL-2 and rIL-4 on the Proliferation and Differentiation of CD25+ B Cell Blasts

|          | [3H]TdR uptake $\times 10^{-3}$ | IgM production $\times 10^{-2}$ |
|----------|---------------------------------|---------------------------------|
| Medium   | 0.5 ± 0.07                      | 1.4 ± 0.08                      |
| rIL-2    | 59.5 ± 0.1                      | 14.9 ± 1.0                      |
| rIL-4    | 9.9 ± 0.6                       | 7.6 ± 0.4                       |
| rIL-4 + rIL-2 | 14.6 ± 0.4                     | 14.4 ± 0.8                      |

B cell blasts recovered after 2 d of activation of high density tonsillar B cells with SAC were positively sorted according to the expression of CD25. Proliferation of CD25+ blasts was determined after 72 h of culture, and IgM production was evaluated after 96 h of culture.

* Purified rIL-2 was used at 10 U/ml.

† Purified rIL-4 was used at 500 U/ml.
antiserum. In the absence of antibody the $[^{3}H]$Tdr uptake in cultures of anti-IgM blasts stimulated with rIL-4, rIL-2, or rIL-2 plus rIL-4 were, respectively: $44 \pm 4.0 \times 10^3$ cpm, $106 \pm 4.0 \times 10^3$ cpm, and $62 \pm 2.0 \times 10^3$ cpm. When anti-IL-4 antiserum is added at the onset of the culture or 7 h after the onset of the culture, the inhibitory effect of rIL-4 is totally blocked (levels of $[^{3}H]$Tdr uptake being respectively, 90 and 98% of the level of $[^{3}H]$Tdr uptake induced by rIL-2 alone). After 24 h of culture, addition of anti-IL-4 antiserum no longer blocks the inhibitory effect of rIL-4. The presence of the control antiserum did not affect rIL-4-mediated inhibition of rIL-2-dependent B cell proliferation, whatever the time of its addition. These data demonstrate that the inhibition observed with rIL-4 is not due to contaminants and that rIL-4 needs to be present for more than 24 h to fully deliver its antagonizing effect.

Discussion

In this report, we have studied the proliferation and differentiation of preactivated tonsillar human B cells in response to combinations of purified rIL-2 and rIL-4. With the majority of the tonsillar B cell preparations, it was found that the maximal proliferative response was higher with rIL-2 than with rIL-4 provided that these factors were both used at optimal concentration. It was repeatedly observed that
combinations of rIL-2 and rIL-4 resulted in proliferation that was lower than that observed with rIL-2 alone and often equivalent to that observed with rIL-4. rIL-4 reduced the levels of [3H]TdR uptake (Table I) induced by rIL-2 as well as the number of cells cycling in response to rIL-2 (Table II). The antagonizing effect of rIL-4 was a function of its concentration, and relatively low amounts of rIL-4 (12.5 U/ml) were sufficient to provide nearly maximum inhibition. Two lines of evidence demonstrated that the inhibitory effects of rIL-4 could not be due to contaminants: first, highly purified rIL-4 was used in all the experiments; second, the inhibitory effect of rIL-4 could be totally reversed by a neutralizing polyclonal anti-IL-4 antisem. The inhibitory effect of rIL-4 was not due to a delayed response to rIL-2, since the inhibition of [3H]TdR incorporation was observed from day 3 to 6. As shown by phenotypic analysis with anti-CD2 and anti-CD20 mAbs, the cell populations cultured with rIL-2, rIL-4, or rIL-4 plus rIL-2 were composed of >95% B cells, whereas T cells and monocytes remained below the levels of detection. Therefore, it is unlikely that the growth inhibitory effect of IL-4 could be mediated via a non-B cell population.

Treatment of anti-IgM as well as SAC preactivated B cells with rIL-4 for 24 h significantly reduced their subsequent proliferation in response to rIL-2. Delayed addition of the neutralizing anti-IL-4 antisem to anti-IgM blasts cultured with rIL-4 and rIL-2 established that the inhibitory effect of rIL-4 on rIL-2-induced proliferation required cells to be in contact with rIL-4 for at least 24 h. This also corresponds to the minimum length of time necessary for rIL-4 to display B cell growth factor activity (20). In contrast, resting B cells pretreated with rIL-4 were still able to fully respond to the growth-promoting activity of rIL-2 in combination with anti-IgM antibody. Nevertheless, readdition of rIL-4 together with rIL-2 and anti-IgM antibody in the second culture period could still block the rIL-2-mediated proliferative response of these cells. These findings suggest that in vitro activation of B cells with anti-IgM antibody or SAC before treatment with rIL-4 or together with rIL-4 is necessary for development of the inhibitory effect of rIL-4.

Experiments performed on SAC blasts demonstrated that rIL-4 did not suppress rIL-2-induced Ig synthesis. rIL-4 did not significantly potentiate Ig production induced by rIL-2 (used at optimal concentration), therefore suggesting that the antagonistic activity of rIL-4 on B cell proliferation induced by IL-2 was not due to an enhancing effect of rIL-4 on rIL-2-mediated differentiation. However, the possibility remained that the apparently unchanged levels of Ig production detected in the rIL-2 plus rIL-4-stimulated cultures compared with the rIL-2-stimulated cultures was in fact reflecting the sum of rIL-4-induced Ig secretion and reduced rIL-2-mediated Ig secretion. This hypothesis was ruled out by the IgA results (Table III), which demonstrate that rIL-4 (which does not induce significant production of IgA by itself) does not suppress rIL-2-mediated IgA production.

In view of the fact that IL-4 can cooperate with IFN-γ and LMW BCGF for B cell proliferation (20) and with IL-2 for T cell proliferation (22), the counteracting effect of IL-4 on the B cell growth-promoting activity of IL-2 was an unexpected finding. However, there is now growing evidence that IL-4 can deliver negative signals to various cell types. Indeed, it has been demonstrated that IL-4 suppresses the generation of LAK cells from PBL by IL-2 (42, 43). Moreover, IL-4 has been shown to inhibit the factor-dependent growth of pre-B cells from bone marrow precursors
In addition, our finding that IL-4 antagonizes IL-2-dependent growth of activated normal B cells is in line with the recent data obtained with chronic lymphocytic leukemia B cells (B-CLL), whose IL-2-dependent proliferation is totally blocked by IL-4 (45). Our data thus indicate that the IL-4-mediated inhibition of IL-2-dependent growth of B-CLL cells is not merely due to the transformed state of these cells. This suggests that B-CLL cells might represent the malignant counterpart of the normal B cell subset sensitive to the antagonizing activity of IL-4.

The contrasting effects of IL-4 on IL-2-mediated proliferation and differentiation of preactivated human B cells suggest that these two IL-2-dependent events may be dissociated. Whether this dissociation is linked to the existence of two different B cell subsets, one differentiating and one proliferating in response to IL-2, remains to be determined. However, in line with this hypothesis, there are now reports that tend to support the notion that activated B cells can be separated according to their capacity to proliferate or differentiate in response to T cell factors. It has been shown that the B cell subset that proliferates in response to SAC is different from that which differentiates in response to SAC and irradiated T cells, and that these two populations can be separated by their ability or inability to form rosettes with mouse erythrocytes (46). Moreover, Nakagawa et al. (47) recently demonstrated that SAC-activated B cell blasts can be divided into subsets that either differentiate or proliferate in response to IL-2. It is thus tempting to speculate that the subpopulation proliferating in response to IL-2 is the target of the IL-4 inhibitory effects, whereas the subpopulation differentiating in response to IL-2 is not affected by IL-4. It is likely that the B cell subpopulations differentiating in response to IL-2 and IL-4 may largely overlap, since the differentiative activities of both lymphokines used at optimal concentration are not additive, whereas they are roughly additive at suboptimal concentrations. In a first attempt to separate IL-2- and IL-4-responsive populations, we sorted out CD25+ and CD25− B cells from a total population of SAC-activated blasts. It was found that B cells that did not express CD25 could not proliferate or differentiate in response to rIL-2 or rIL-4. Thus, cells proliferating and differentiating in response to rIL-2 or rIL-4 were included within the CD25+ subset. These experiments also confirmed, at the level of a B cell subpopulation selected on the expression of the IL-2 receptor, that rIL-4 can antagonize rIL-2-mediated B cell growth without affecting rIL-2-induced Ig production. Presently, we can only speculate on the nature of the mechanism involved in the inhibitory activity of IL-4. An IL-4-mediated downregulation of the expression of the IL-2 receptor heterodimer could be a possible explanation. Binding experiments are presently being performed to challenge this hypothesis.

The data presented in this report demonstrate that, in addition to its stimulatory effects on the immune response, IL-4 delivers inhibitory signals to B cells. This finding adds further complexity to the understanding of the sequence of events that affect a B cell once it has encountered its specific antigen.

**Summary**

The combined effect of IL-4 and IL-2 on proliferation of anti-IgM antibody or Staphylococcus aureus strain Cowan I (SAC)-preactivated B cells was investigated. It was observed that in most cases, rIL-2 used at optimal concentration induced higher levels of tritiated thymidine ([3H]TdR) uptake than rIL-4 used at optimal concen-
INTERLEUKIN 4 BLOCKS INTERLEUKIN 2 B CELL GROWTH

When rIL-4 and rIL-2 were added together, it was repeatedly found that B cell proliferation induced by rIL-2 was significantly reduced and was, in most cases, comparable with the proliferation induced by rIL-4 alone. Cell cycle studies demonstrated that rIL-4 significantly reduced the number of cells entering S and G2/M phases of the cell cycle upon rIL-2 stimulation. B cell blasts preincubated for 24 or 48 h with rIL-4 displayed a reduced proliferation in response to rIL-2. In contrast, preculture of resting B cells with rIL-4 did not impair their subsequent proliferation in response to rIL-2 plus insolubilized anti-IgM antibody. This suggests that rIL-4 can only exert its inhibitory effect once B cells have received an activation signal. The differentiative activity of rIL-2 measured on B cell blasts preactivated for 2 d with SAC was not altered by rIL-4, which suggests that rIL-4 did not exert its inhibitory activity on rIL-2-induced B cell proliferation by enhancing rIL-2-mediated differentiation. Delayed addition of a neutralizing anti-IL-4 antisem demonstrated that a period of contact of at least 24 h between IL-4 and B cell blasts was necessary for the development of the antagonistic effect of IL-4 on IL-2-mediated growth of activated B cells. These data demonstrate that IL-4 antagonizes the B cell growth-promoting effect of IL-2 without affecting the differentiation of preactivated B cells in response to IL-2.

We thank Dr. Allan Waitz and Francine Brière for careful review of the manuscript, Isabelle Durand for expert assistance with flow cytometry, Isabelle Chrétien for providing the anti-IL-4 antisem, and Nicole Courbière for excellent secretarial assistance.

Received for publication 28 March 1988 and in revised form 5 July 1988.

References

1. Kishimoto, T. 1987. B-cell stimulatory factors (BSFs): molecular structure, biological function and regulation of expression. J. Immunol. 7:343.
2. O'Garra, A., S. Umland, T. Defrance, and J. Christiansen. 1988. "B-cell factors" are pleiotropic. Immunol. Today. 9:45.
3. Mingari, M. C., F. Gerossi, G. Carra, R. S. Accolla, A. Moretta, R. H. Zubler, T. A. Waldmann, and L. Moretta. 1984. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature (Lond). 312:641.
4. Romagnani, S., M. G. Givozi, R. Biagiotti, F. Almerigogna, C. Mingari, E. Maggi, C. Liang, and L. Moretta. 1986. B-cell growth factor activity of interferon-γ. Reombinant human interferon-γ promotes proliferation of anti-μ activated human B lymphocytes. J. Immunol. 136:3513.
5. Defrance, T., J. P. Aubry, B. Vanbervliet, and J. Banchereau. 1986. Human interferon-γ acts as a B cell growth factor in the anti-IgM antibody co-stimulatory assay but has no direct B cell differentiation activity. J. Immunol. 137:3861.
6. Morikawa, K., H. Kubagawa, T. Suzuki, and M. Cooper. 1987. Recombinant interferon-α, β, and γ enhance the proliferative response of human B cells. J. Immunol. 139:761.
7. Kehri, J. H., A. Miller, and A. S. Fauci. 1987. Effect of tumor necrosis factor α on mitogen-activated human B cells. J. Exp. Med. 166:786.
8. Kehri, J. H., M. Alvarez-Mon, G. A. Delsing, and A. S. Fauci. 1987. Lymphotoxin is an important T cell-derived growth factor for human B cells. Science (Wash. DC). 238:1144.
9. Sharma, D., S. Mehta, J. Morgan, and A. Maizel. 1987. Molecular cloning and expression of a human B cell growth factor gene in Escherichia coli. Science (Wash. DC). 235:1489.
10. Ambrus, J. L., C. H. Jurgensen, E. J. Brown, and A. S. Fauci. 1985. Purification to homogeneity of a high molecular weight human B cell growth factor: demonstration of
specific binding to activated B cells; and development of a monoclonal antibody to the factor. J. Exp. Med. 162:1319.

11. Dugas, B., A. Vasquez, J. P. Gerard, Y. Richard, M. T. Auffredou, J. F. Delfraissy, D. Fradelizi, and P. Galanaud. 1985. Functional properties of two human B cell growth factor species separated by lectin affinity column. J. Immunol. 135:333.

12. Muruguchi, A., J. Kehrl, D. L. Longo, D. J. Volkman, K. A. Smith, and A. S. Fauci. 1985. Interleukin-2 receptors on human B cells. Implications for the role of interleukin-2 in human B cell functions. J. Exp. Med. 161:181.

13. Azuma, C., T. Tamabe, M. Konishi, T. Kinashi, T. Noma, F. Matsuda, Y. Yaoita, K. Takatsu, L. Hammarström, C. I. E. Smith, E. Severinson, and T. Honjo. 1986. Cloning of cDNA for human T-cell replacing factor (interleukin 5) and comparison with the murine homologue. Nucleic Acids Res. 14:9149.

14. Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Matsui, Y. Takahara, T. Tanahara, and T. Kishimoto. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (Lond.). 324:73.

15. Zilberstein, A., R. Ruggieri, J. H. Korn, and M. Revel. 1986. Structure and expression of cDNA and genes for human interferon-β-2, a distinct species inducible by growth-stimulatory cytokines. EMBO (Eur. J. Mol. Biol. Organ.) J. 5:2529.

16. Billiau, A. 1986. BSF-2 is not just a differentiation factor. Nature (Lond.). 324:415.

17. Paul, W. E., and J. Ohara. 1987. B-cell stimulatory factor 1/interleukin 4. Annu. Rev. Immunol. 5:429.

18. Yokota, T., N. Arai, J. E. de Vries, H. Spits, J. Banchereau, A. Zlotnick, D. Rennick, M. Howard, Y. Takebe, S. Miyatake, F. Lee, and K. Arai. 1988. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells, and hemopoietic cells. Immunol. Rev. 102:137.

19. Howard, M., J. Farrar, M. Hilfiker, B. Johnson, K. Takatsu, T. Hamaoka, and W. E. Paul. 1982. Identification of a T-cell-derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 155:914.

20. Defrance, T., B. Vanbervliet, J. P. Aubry, Y. Takebe, N. Arai, A. Miyajima, T. Yokota, F. Lee, K. Arai, J. E. de Vries, and J. Banchereau. 1987. B cell growth-promoting activity of recombinant human interleukin 4. J. Immunol. 139:1135.

21. Naka, H., E. M. Reve, J. Mizuguchi, J. Ohara, T. Mosmann, and W. E. Paul. 1987. B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J. Exp. Med. 165:157.

22. Spits, H., H. Yssel, Y. Takebe, N. Arai, T. Yokota, F. Lee, K. Arai, J. Banchereau, and J. E. de Vries. 1987. Recombinant interleukin 4 promotes the growth of human T cells. J. Immunol. 139:1142.

23. Bonnefoy, J. Y., J. P. Aubry, C. Peronne, J. Wijdenes, and J. Banchereau. 1987. Production and characterization of a monoclonal antibody specific for the human low affinity receptor for IgE: CD23 is a low affinity receptor for IgE. J. Immunol. 138:2970.

24. Yukawa, K., H. Kikutani, H. Owaki, Y. Yamasaki, A. Yokota, K. Nakamura, E. L. Barshumian, R. R. Hardy, M. Suemura, and T. Kishimoto. 1987. A B cell-specific differentiation antigen, CD23, is a receptor for IgE (FceR) on lymphocytes. J. Immunol. 138:2576.

25. Defrance, T., J. P. Aubry, F. Rousset, B. Vanbervliet, J. Y. Bonnefoy, N. Arai, Y. Takebe, T. Yokota, F. Lee, K. Arai, J. E. de Vries, and J. Banchereau. 1987. Human recombinant interleukin 4 induces Fce receptors (CD23) on normal human B lymphocytes. J. Exp. Med. 165:1459.

26. Hudak, S. A., S. O. Gollnick, D. H. Conrad, and M. H. Kehry. 1987. Murine-B cell stimulatory factor-I (interleukin 4) increases expression of the Fc receptor for IgE on mouse B cells. Proc. Natl. Acad. Sci. USA. 84:4606.
133 6

INTERLEUKIN 4 BLOCKS INTERLEUKIN 2 B CELL GROWTH

27. Rousett, E., R. de Waal Malefijt, B. Slierendregt, J. P. Aubry, J. Y. Bonnefoy, T. Defrance, J. Banchereau, and J. E. de Vries. 1988. Regulation of Fc-receptor for IgE (CD23) and class II MHC antigen expression on Burkitt lymphoma cell lines by human interleukin 4 and interferon-γ. J. Immunol. 140:2625.

28. Coffman, R. L., B. W. P. Seymour, D. A. Lebman, D. D. Hiraki, J. A. Christiansen, B. Shrader, H. M. Cherwinski, H. F. J. Savelkoul, F. D. Finkelman, M. W. Bond, and T. R. Mosmann. 1988. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102:5.

29. Pène, J., F. Rousett, F. Brière, I. Chrétien, J. Y. Bonnefoy, H. Spits, T. Yokota, N. Arai, K. Arai, J. Banchereau, and J. E. de Vries. 1988. IgE production by normal human lymphocytes is induced by IL-4 and suppressed by interferons α, γ, and prostaglandin E 2. Proc. Natl. Acad. Sci. USA. In press.

30. Bonnefoy, J. Y., T. Defrance, C. Peronne, C. Menetrier, F. Rousett, J. Pène, J. E. de Vries, and J. Banchereau. 1988. Human recombinant IL-4 induces normal B-cells to produce a soluble CD23/IgE binding factor analogous to that spontaneously released by lymphoblastoid B-cell lines. Eur. J. Immunol. 18:117.

31. Defrance, T., B. Vanbervliet, J. Pène, and J. Banchereau. 1988. Human recombinant IL-4 induces activated B lymphocytes to produce IgG and IgM. J. Immunol. In press.

32. Nakagawa, T., T. Hirano, N. Nakagawa, K. Yoshizaki, and T. Kishimoto. 1985. Effect of recombinant IL-2 and IFN-γ on proliferation and differentiation of human B cells. J. Immunol. 135:959.

33. Lé thi Bich-Thuy, C. Queen, and A. Fauci. 1986. Interferon-γ induces light chain synthesis in interleukin 2 stimulated human B cells. Eur. J. Immunol. 16:547.

34. Romagnani, S., G. M. Giudizi, E. Maggi, F. Almerigogna, R. Biagiotti, G. Del Prete, M. Mazzetti, A. Alessi, D. Vercelli, and M. Rici. 1985. Synergy of B cell growth factor and interleukin 2 in the proliferation of activated human B cells. Eur. J. Immunol. 15:1158.

35. Romagnani, S., G. M. Giudizi, F. Almerigogna, R. Biagiotti, A. Alessi, C. Mingari, C. M. Liang, L. Moretta, and M. Rici. 1986. Analysis of the role of interferon-gamma, interleukin 2 and a third factor distinct from interferon-gamma and interleukin 2 on human B cell proliferation. Evidence that they act at different times after B cell activation. Eur. J. Immunol. 16:623.

36. Yokota, T., T. Otsuka, T. R. Mosmann, J. Banchereau, T. Defrance, D. Blanchard, J. E. de Vries, F. Lee, and K. Arai. 1986. Isolation and characterization of a human interleukin CDNA clone, homologous to mouse BSF-1, which expresses B cell and T cell stimulating activities. Proc. Natl. Acad. Sci. USA. 83:5894.

37. Yssel, H., J. E. de Vries, M. Koken, W. Van Blitterswijk, and H. Spits. 1984. Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones. J. Immunol. Methods. 72:219.

38. Taylor, I. W. 1980. A rapid single step staining technique for DNA analysis by flow microfluorimetry. J. Histochem. Cytochem. 28:1021.

39. Dolbeare, F., H. G. Gratzner, M. G. Pallavicini, and J. W. Gray. 1983. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. Acad. Sci. USA. 80:5573.

40. Dean, P. N., and J. H. Jett. 1974. Mathematical analysis of DNA distributions derived from flow microfluorimetry. J. Cell Biol. 60:523.

41. Voller, A. 1980. Heterogenous enzyme-immunoassays and their applications. Enzyme-Imunoassay. E. T. Maggio, editor. CRC Press, Boca Raton, FL. 181.

42. Widmer, M. B., R. B. Acres, H. M. Sassenfield, and K. H. Grabstein. 1987. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J. Exp. Med. 166:1447.

43. Spits, H., H. Yssel, X. Paliard, R. Kastelein, C. Figdor, and J. E. de Vries. 1988. Inter-
leukin 4 inhibits interleukin 2 mediated induction of human lymphokine activated killer cells, but augments the generation of antigen specific cytotoxic T lymphocytes in mixed leucocyte cultures. *J. Immunol.* In press.

44. Rennick, D., G. Yang, C. Muller-Sieburg, C. Smith, N. Arai, Y. Takabe, and L. Gemmell. 1987. Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hemopoietic progenitor cells. *Proc. Natl. Acad. Sci. USA.* 84:6889.

45. S. Karray, T. Defrance, H. Merle-Béral, J. Banchereau, P. Debré, and P. Galanaud. 1988. Interleukin 4 counteracts the interleukin 2-induced proliferation of monoclonal B cells. *J. Exp. Med.* 168:85.

46. Ito, S., and A. R. Lawton. 1984. Response of human B cells to Staphylococcus aureus strain Cowan I: T independent proliferation and T-dependent differentiation to immunoglobulin secretion involve subsets separable by rosetting with mouse erythrocytes. *J. Immunol.* 133:1891.

47. Nakagawa, T., N. Nakagawa, H. Goldstein, D. J. Volkman, and A. S. Fauci. 1986. Demonstration that human B cells respond differently to interleukin 2 and B cell differentiation factor based on their stages of maturation. *J. Immunol.* 137:3175.